Applicant, as named in the Orange Book

Acadia Pharms Inc

Acadia Pharmaceuticals Inc · Nasdaq: ACAD

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Nuplazid on 23 Sep 2037. 4 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Nuplazid NDA 207318 pimavanserin tartrate	pimavanserin tartrate	23 Sep 2037 patent	patent
Nuplazid NDA 210793 pimavanserin tartrate	pimavanserin tartrate	27 Feb 2039 patent	patent
Daybue NDA 217026 trofinetide	trofinetide	12 Jan 2043 patent	patent
Daybue Stix NDA 219884 · 3 strengths trofinetide	trofinetide	12 Jan 2043 patent	patent

Nuplazid · Generic tentatively approved · ANDA 214750, Teva Pharms UsaTentative approval 2 Sep 2026Detected 25 Oct 2026